| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Integra Lifesciences (NASDAQ:IART) reported its Q4 earnings results on Wednesday, February 28, 2024 at 06:00 AM.
Here's what investors need to know about the announcement.
Integra Lifesciences missed estimated earnings by -1.0%, reporting an EPS of $0.89 versus an estimate of $0.9.
Revenue was down $983 thousand from the same period last year.
Last quarter the company missed on EPS by $0.02 which was followed by a 1.0% increase in the share price the next day.
Here's a look at Integra Lifesciences's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | 0.78 | 0.57 | 0.74 | 0.90 |
| EPS Actual | 0.76 | 0.71 | 0.74 | 0.94 |
| Revenue Estimate | 387.12M | 374.07M | 373.21M | 397.95M |
| Revenue Actual | 382.42M | 381.30M | 380.85M | 398.02M |
To track all earnings releases for Integra Lifesciences visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: IART
